218 results on '"Nilotinib -- Research"'
Search Results
2. Findings from Mansoura University Broaden Understanding of Chronic Myeloid Leukemia [The Utility of Insulin Like Growth Factor Binding Proteins (Igfbps-1, 2, 3) With Genes Expression In Resistance To Imatinib and Nilotinib In Chronic Myeloid ...]
3. Recent Findings from University of Nis Highlight Research in Pathophysiology (Low Renalase Levels in Newly Diagnosed CML: Dysregulation Sensitive to Modulation by Tyrosine Kinase Inhibitors)
4. Studies from University of Kansas Medical Center Further Understanding of Tyrosine Kinase Inhibitors (Systematic Approach to Treatment De-Escalation While Maintaining Remission in CML, a Risk Mitigation and Cost Reduction Study)
5. Medical College of Wisconsin Researcher Describes Research in Chronic Myeloid Leukemia [Treatment with Asciminib As a Second Line after One Prior Tyrosine Kinase Inhibitor (TKI) in Patients with Chronic-Phase Chronic Myeloid Leukemia (CML-CP) - ...]
6. Hannover Medical School Researcher Yields New Data on Chronic Myeloid Leukemia [Second-Line Bosutinib Is Effective and Feasible in Patients Failing Second Generation TKI (2G-TKI) in Chronic Phase Chronic Myeloid Leukemia (CML) - an Analysis of a ...]
7. Data on Chronic Myeloid Leukemia Published by a Researcher at Tor Vergata University of Rome [Assessment of Transitioning from High-Potency to Low-Potency Inhibitors in Chronic Myeloid Leukemia (CML) Patients: The Downgrading-Impact Project, a ...]
8. Chiang Mai University Researcher Describes Findings in Vitamin D Deficiency (Vitamin D Deficiency Negatively Affects Responses in Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors)
9. Research from University of Utah Reveals New Findings on Chronic Myeloid Leukemia (Disparities in frontline treatment and overall survival in the era of targeted tyrosine kinase inhibitor therapy for chronic myeloid leukemia: 2004-2021)
10. New Chronic Myeloid Leukemia Findings from Pontificia Universidad Catolica de Chile Described (New Inhibitors of Bcr-Abl Based on 2,6,9-Trisubstituted Purine Scaffold Elicit Cytotoxicity in Chronic Myeloid Leukemia-Derived Cell Lines Sensitive ...)
11. Studies from Hunan University of Science and Engineering Update Current Data on Drugs and Therapies (An Investigation of the Impact of Precipitation Temperature and Filter Cake Thickness on the Physical Stability of Amorphous Solids: A Case ...)
12. Data on Drugs and Therapies Detailed by a Researcher at Hunan University of Science and Engineering (The Optimization of Pair Distribution Functions for the Evaluation of the Degree of Disorder and Physical Stability in Amorphous Solids)
13. Novartis announces its Phase III study of Scemblix showed 'superior efficacy'
14. Researcher from Nanchang University Reports Details of New Studies and Findings in the Area of Ovarian Cancer (Machine learning developed a fibroblast-related signature for predicting clinical outcome and drug sensitivity in ovarian cancer)
15. New BCR-ABL Tyrosine Kinase Inhibitors Research from Northwestern University Feinberg School of Medicine Discussed (Nilotinib-induced alterations in endothelial cell function recapitulate clinical vascular phenotypes independent of ABL1)
16. Hunan University of Science and Engineering Researcher Illuminates Research in Drugs and Therapies (Investigation of the Influence of Anti-Solvent Precipitation Parameters on the Physical Stability of Amorphous Solids)
17. Affiliated Hospital of North Sichuan Medical College Researchers Discuss Findings in Chronic Myeloid Leukemia (Efficacy and safety of switching to flumatinib in patients with chronic myeloid leukemia who have not achieved optimal response or ...)
18. New Obesity, Fitness and Wellness Data Have Been Reported by Researchers at Hunan University of Science and Engineering (Optimization of Precipitation Conditions for Producing Physically Stable Amorphous Solids Using Pair Distribution Function ...)
19. New Findings from Augusta University in the Area of Chronic Myeloid Leukemia Published [Asciminib (ASC) Demonstrates Favorable Safety and Tolerability Compared with Each Investigator-Selected Tyrosine Kinase Inhibitor (IS TKI) in Newly Diagnosed ...]
20. New Chronic Myelogenous Leukemia Data Has Been Reported by a Researcher at Cleveland Clinic (Outcomes of Second-Line Tyrosine Kinase Inhibitors after First-Line Imatinib in Chronic Myelogenous Leukemia: A Retrospective Cohort Study)
21. Studies from Cleveland Clinic in the Area of Chronic Myelogenous Leukemia Described (Cardiovascular Profile of Tyrosine Kinase Inhibitors in Chronic Myelogenous Leukemia: A 16-Year Observational Study)
22. Studies from Korea Cancer Center Hospital Have Provided New Information about Drug Research (A Rare Case of X-linked Four-way Philadelphia Chromosome Translocation With Therapeutic Challenges and Clonal Evolution)
23. Research Conducted at University of Medicine and Pharmacy of Craiova Has Provided New Information about Cancer (Quantitative Analysis of Sorafenib and Nilotinib In Human Plasma By Spe-lc-ms)
24. Researcher from Radboud University Medical Center Details New Studies and Findings in the Area of Chronic Myeloid Leukemia (Transporter-Mediated Cellular Distribution of Tyrosine Kinase Inhibitors as a Potential Resistance Mechanism in Chronic ...)
25. Studies from Instituto Nacional de Cancer (INCA) Further Understanding of Chronic Myeloid Leukemia (Bcr-abl Exon 7 Deletion in Chronic Myeloid Leukemia: Challenges in Point Mutations Analysis)
26. Study Findings on Melanoma Described by Researchers at Hubei University of Medicine (Clarifying new molecular subtyping and precise treatment of melanoma based on disulfidptosis-related lncRNA signature)
27. Study Data from University of Texas MD Anderson Cancer Center Provide New Insights into Chronic Myeloid Leukemia (Chronic Myeloid Leukemia: 2025 Update On Diagnosis, Therapy, and Monitoring)
28. Xspray Pharma's XS003 Study Shows Matching Bioavailability to Tasigna at More than a 50% Lower Dose
29. Xspray Pharma's XS003 Study shows Matching Bioavailability to Tasigna at more than a 50% Lower Dose
30. Xspray Pharma's XS003 Study Shows Matching Bioavailability to Tasigna at More than a 50% Lower Dose
31. Reports Outline Chronic Myeloid Leukemia Study Results from Hospital Universitario Nuestra Senora de Candelaria (Risk factors determining adherence to tyrosine kinase inhibitors in chronic myeloid leukaemia)
32. Reports from Centre Leon Berard Describe Recent Advances in Chronic Myeloid Leukemia (A Multicenter Retrospective Chart Review Study of Treatment and Disease Patterns and Clinical Outcomes of Patients with Chronic-Phase Chronic Myeloid Leukemia ...)
33. Study Findings on Chronic Myeloid Leukemia Published by a Researcher at Tor Vergata University of Rome [Minimal Residual Disease Detection at RNA and Leukemic Stem Cell (LSC) Levels: Comparison of RT-qPCR, d-PCR and CD26+ Stem Cell Measurements ...]
34. University of Siena Researchers Discuss Findings in Chronic Myeloid Leukemia (Prospective monitoring of chronic myeloid leukemia patients from the time of TKI discontinuation: the fate of peripheral blood CD26+ leukemia stem cells)
35. Data on Drug Targets Described by Researchers at Deakin University (Explaining Black Box Drug Target Prediction Through Model Agnostic Counterfactual Samples)
36. Studies from Bulgarian Academy of Sciences Provide New Data on Cancer (Ferrocene Modified Analogues of Imatinib and Nilotinib As Potent Anti-cancer Agents)
37. Terns Pharmaceuticals Announces Data from Ongoing Phase 1 Pharmacokinetic Study of Allosteric BCR-ABL Inhibitor TERN-701 in Adult Healthy Volunteers and Highlights Potential for Competitive Differentiation
38. Pharmaceutical Clinical Trials And Patentability At The EPO
39. Findings from Jagiellonian University Update Knowledge of Chronic Myeloid Leukemia (Endothelial Function In Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors Is Not Related To Cardiovascular Risk Assessed By the ...)
40. New Findings from Masaryk University Update Understanding of Chronic Myeloid Leukemia (Expansions of Tumor-reactive Vdelta1 Gamma-delta T Cells In Newly Diagnosed Patients With Chronic Myeloid Leukemia)
41. JSS Academy of Higher Education and Research Researchers Report Recent Findings in Dry Eye Syndrome (Unveiling molecular insights: in silico exploration of TLR4 antagonist for management of dry eye syndrome)
42. Findings on Obesity, Fitness and Wellness Detailed by Investigators at University of Ioannina (Expressing Enhanced Inhibitory Effects Toward Arachidonic Acid Induced Platelet Activation: Design, Synthesis, Dft Calculations and In Vitro ...)
43. Research from University of Patras School of Medicine Provides New Study Findings on Chronic Myeloid Leukemia (Safety and Tolerability of Nilotinib in Patients with Chronic Myeloid Leukemia during Routine Clinical Practice: Results from the ...)
44. New Chronic Myeloid Leukemia Research from American University of Beirut Outlined (Safety and Efficacy of Elective Switch from Nilotinib to Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia)
45. Research Reports on Chronic Myeloid Leukemia from Kermanshah University of Medical Sciences Provide New Insights (Coexistence of BCR-ABL1 Translocation and JAK2 V617F Mutation in a Patient with Chronic Myeloid Leukemia Under Long-term Treatment ...)
46. Georgetown University Medical Center Researchers Update Knowledge of Huntington Disease (Alteration of Autophagy and Glial Activity in Nilotinib-Treated Huntington's Disease Patients)
47. Kantonsspital Aarau Researchers Update Current Study Findings on Chronic Myeloid Leukemia (A multicenter real-world evidence study in the Swiss treatment landscape of chronic myeloid leukemia)
48. Research Results from University Hospital de Gran Canaria Dr. Negrin Update Knowledge of Chronic Myeloid Leukemia (The Cardiovascular Event Risk Associated with Tyrosine Kinase Inhibitors and the Lipid Profile in Patients with Chronic Myeloid ...)
49. New Melanoma Study Findings Reported from Gyeongsang National University (Regulation of Cell Cycle Progression through RB Phosphorylation by Nilotinib and AT-9283 in Human Melanoma A375P Cells)
50. Studies from Fudan University Describe New Findings in Adenocarcinoma (Complement system-related genes in stomach adenocarcinoma: Prognostic signature, immune landscape, and drug resistance)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.